文献速递新生儿儿童感染

2009至2017年美国新生儿重症监护病房婴儿大肠埃希菌抗生素敏感性分析

Antibiotic Susceptibility of Escherichia coli Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017.
PubMed 文献 · JAMA Pediatr · 2021-01-01

该回顾性队列研究利用Premier健康数据库,分析了2009至2017年美国69个中心721例发生大肠埃希菌感染的新生儿。研究发现,对氨苄西林不耐药比例年均约66.8%,对氨基糖苷类不耐药比例年均约16.8%,产超广谱β-内酰胺酶表型年均约5.0%,均无显著时间变化。早发型感染患儿中10.1%对氨苄西林和庆大霉素均不耐药。

要点

  • 新生儿大肠埃希菌对氨苄西林不耐药比例高,年均约66.8%,2009至2017年无显著变化。
  • 早发型感染中10.1%的分离株对氨苄西林和庆大霉素均不耐药,提示经验性用药需谨慎。
  • 未发现对碳青霉烯类不耐药的分离株。

核心结论

  • 新生儿大肠埃希菌对常用抗生素的不耐药比例较高,且2009至2017年间无显著变化,可能为新生儿经验性抗生素选择提供参考。

主要发现

  • 共721例婴儿(男434例,60.2%;感染中位日龄14天,四分位距1-33天)至少有一次大肠埃希菌感染且药敏结果可用。
  • 对氨苄西林不耐药的年均比例为66.8%(标准差1.5%),范围63.3%至68.6%,估计年变化-0.28%(95%CI -1.75%至1.18%)。
  • 对氨基糖苷类不耐药的年均比例为16.8%(标准差4.5%),范围10.7%至23.2%,估计年变化-0.85%(95%CI -1.93%至0.23%)。
  • 产超广谱β-内酰胺酶表型的年均比例为5.0%(标准差3.7%),范围0%至11.1%,估计年变化0.46%(95%CI -0.18%至1.11%)。
  • 218例早发型感染婴儿中,22例(10.1%)分离株对氨苄西林和庆大霉素均不耐药;未发现对碳青霉烯类不耐药的分离株。

临床怎么用

  • 新生儿经验性抗生素选择时应考虑大肠埃希菌对氨苄西林和庆大霉素的不耐药比例较高,尤其早发型感染中10.1%对两者均不耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Escherichia coli is a leading cause of serious infection among term and preterm newborn infants. Surveillance of antibiotic susceptibility patterns of E coli among infants admitted to neonatal intensive care units should inform empirical antibiotic administration. OBJECTIVE: To assess the epidemiologic characteristics and antibiotic susceptibility patterns of E coli in infants admitted to neonatal intensive care units in the US over time. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used the Premier Health Database, a comprehensive administrative database of inpatient encounters from academic and community hospitals across the US. Participants included newborn infants admitted to centers contributing microbiology data from January 1, 2009, to December 31, 2017, with E coli isolated from blood, cerebrospinal fluid, or urine cultures. Data were collected and analyzed from December 1, 2018, to November 30, 2019. MAIN OUTCOMES AND MEASURES: Changes in annual antibiotic susceptibility of E coli during the study period. The proportion of infants with nonsusceptible organisms (resistant or intermediate susceptibility) in antibiotic categories by year, birth weight, infection source, and timing of infection and patient and center characteristics associated with neonatal E coli infection and antibiotic susceptibility were assessed. RESULTS: A total of 721 infants (434 male [60.2%]; median age at E coli infection, 14 days [interquartile range, 1-33 days]) from 69 centers had at least 1 episode of E coli infection and available susceptibility results. No significant changes were observed over time in the overall annual proportions of antibiotic nonsusceptibility to ampicillin (mean [SD], 66.8% [1.5%]; range, 63.3% to 68.6%; estimated yearly change, -0.28% [95% CI, -1.75% to 1.18%]), nonsusceptibility to aminoglycosides (mean [SD], 16.8% [4.5%]; range, 10.7% to 23.2%; estimated yearly change, -0.85% [95% CI, -1.93% to 0.23%]), or extended-spectrum β-lactamase phenotype (mean [SD], 5.0% [3.7%]; range, 0% to 11.1%; estimated yearly change, 0.46% [95% CI, -0.18% to 1.11%]). No isolates with nonsusceptibility to carbapenems were identified. Among 218 infants with early-onset infection, 22 (10.1%) had isolates with nonsusceptibility to both ampicillin and gentamicin, the antibiotics most commonly administered to newborns as empirical therapy. CONCLUSIONS AND RELEVANCE: In this cohort study, nonsusceptibility to commonly administered antibiotics was found in substantial proportions of neonatal E coli isolates, with no significant change from 2009 to 2017. These findings may inform empirical antibiotic choices for newborn infants.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Flannery DD, Akinboyo IC, Mukhopadhyay S, et al. Antibiotic Susceptibility of Escherichia coli Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017. JAMA Pediatr. 2021. PMID: 33165599. doi:10.1001/jamapediatrics.2020.4719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。